Search clinical trials for: Camrelizumab ＋Immunotherapy

Total 957 results

Zhejiang Cancer Hospital

Recruiting

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Brain Metastases | NSCLC Stage IV | Immunotherapy

China
Beijing Chao Yang Hospital

Recruiting

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (NACSOC-02)

Colorectal Cancer | Obstruction | Immunotherapy | Neoadjuvant Chemotherapy | Stent

China
Peking University Cancer Hospital & Institute
Beijing Nanjiao Cancer Hospital

Recruiting

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Rectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Zhejiang Cancer Hospital

Recruiting

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Esophageal Cancer

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Jiangsu Cancer Institute & Hospital

Recruiting

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
Peking University

Not yet recruiting

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Esophageal Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (ESCC)

Esophageal Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Oligometastasis | Radiotherapy

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Fujian Medical University Union Hospital

Recruiting

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Radiotherapy | Immunotherapy | Esophageal Neoplasm

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

HNSCC

China
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NSCLC)

NSCLC
Sun Yat-sen University

Recruiting

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Paranasal Sinus Cancer | Induction Chemotherapy | Camrelizumab | Nasal Cavity Cancer | Intensity Modulated Radiotherapy | Concurrent Chemotherapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer (CAN-RESPOND)

Endometrial Cancer
Jiangxi Provincial Cancer Hospital

Recruiting

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Triple-Negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Huashan Hospital
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.

Recruiting

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Power Life Sciences Inc.

Not yet recruiting

Neoadjuvant Immunotherapy in Advanced NSCLC

Lung Cancer, Non-small Cell

United States
Leti Pharma GmbH

Completed

Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients

Allergic Asthma | Allergic Rhinoconjunctivitis

Germany
University Hospital Center of Martinique
European Georges Pompidou Hospital

Completed

Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population (MituHPV)

Immunotherapy

France, Martinique
Washington University School of Medicine

Unknown

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes (MINING)

Melanoma | Skin Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma of the Skin | Autoimmunity

United States
wang shusen

Recruiting

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Melanoma

China
Nanfang Hospital of Southern Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Hepatocellular Carcinoma

China
Peking University First Hospital

Not yet recruiting

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors

Immunotherapy | SBRT | Bulky Tumor
Peking University Third Hospital

Not yet recruiting

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Ovarian Clear Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Guangdong Association of Clinical Trials

Recruiting

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Lung Cancer | Immunotherapy

China
Stanford University

Completed

Longitudinal Follow-up Study for Food Allergies

Food Allergy
National Guard Health Affairs

Unknown

Clinical Utilization of Newly Approved Oncology Medications

Cancer

Saudi Arabia
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Guangdong Association of Clinical Trials

Not yet recruiting

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Non-small Cell Lung Cancer
Beijing Sanbo Brain Hospital

Recruiting

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Primary Central Nervous System Lymphoma

China
Guangdong Association of Clinical Trials

Unknown

Efficacy and Safety of Camrelizumab in Real-World Study

Non-small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Helsinki University Central Hospital

Completed

The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults

Food Allergy

Finland
Brown University

Terminated

Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma (273)

Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Burkitts Lymphoma | T Cell Lymphomas | Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia

United States
HAL Allergy

Completed

SUBLIVAC® Birch PROBE Study

Birch Pollen Allergy | Seasonal Rhinitis and/or Rhinoconjunctivitis

Germany
Meir Medical Center

Completed

Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings

Venom Allergy
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

Malignant Solid Tumour

China

Search clinical trials for: Camrelizumab ＋Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations